• Saket Saini Siddhartha Institute of Pharmacy, Dehradun, Uttarakhand, India
  • Alishan Zia Delhi Institute of Pharmaceutical Sciences and Research, Delhi, India
  • Shaily Tyagi Assistant professor in Quantum university, Roorkee, Uttarakhand, India
  • Himani Nautiyal Associate professor in Siddhartha Institute, Dehradun, Uttarakhand, India




Breast Cancer, Carcinomas, Sarcomas, Leukemia, Lymphomas, Women

Abstract [English]

Cancer is the major health problem worldwide, according to WHO in 2018 cancer is responsible for an estimated 9.6 mill death out of 18.1 million new cases and globally 6 deaths occur due to cancer. Cancer is the abnormal, unwanted growth of cells, when abnormal cells divide in an uncontrolled way within the body and destroy normal tissue that can lead to death. Normal body cell grows, divide, and die in an orderly way or cancer cells are different because they do not die, grow continuously, and divide in orderly way. There are more than 200 types of cancer. Any agent that converts a body cell to develop abnormally can cause cancer. The cancer causative agents include- radiations, chemical or toxic compound exposure, lifestyle, hormones, and human genetics. Most tumors can be categorized as one of the three main groups: carcinomas, sarcomas and leukemia or lymphomas. Carcinomas, which associated around 90% of human cancer, are malignancies of epithelial cell. Sarcomas, which are uncommon in human, are solid tumor of connective tissue including muscle, bone, cartilage, and fibrous tissue. Leukemia and lymphomas, which represent around 8% of human malignancies, emerge from the blood forming cell and from cell of immune system. Carcinoma of breast is a malignant disease with variable outcomes. Breast carcinoma is second most common cause of death in females though it can also occur in men but are very uncommon. This type of cancer is malignant cell growth in breast. This study was done to compare and analyze adverse drug reactions of cancer chemotherapy in breast cancer in a rural hospital. Objectives included- a) To study adverse drug reactions of various chemotherapeutic agents used in patients suffering breast cancer b) To compare various side-effects as a result of different combination protocols to identify the drug protocol with least amounts of adverse drug reactions. However, an extremely significant difference was found between all of the comparison groups studied.


Download data is not yet available.


Ames, B. N., Gold, L. S. and Willett, W. C. (1995). The Cause and Prevention of Cancer. the Proceedings of the National Academy of Sciences, 92(12), 5258-5265. https://doi.org/10.1073/pnas.92.12.5258. DOI: https://doi.org/10.1073/pnas.92.12.5258

Brown, A., Kumar, S. and Tchounwou, P. B. (2019). Cisplatin Based Chemotherapy of Human Cancers. Journal of Cancer Science and Therapy 11(4).

Arruebo, M., Vilaboa, N., and Saez-Gutierrez, B. (2011). Assessment of the Evolution of Cancer Treatment Therapies. Cancers 3(3), 3279-3330. https://doi.org/10.3390/cancers3033279. DOI: https://doi.org/10.3390/cancers3033279

Berry, D. A., Cronin, K. A., and Plevritis, S. K. (2005). Effect of Screening and Adjuvant Therapy on Mortality From Breast Cancer. The New England Journal of Medicine, 353, 1784-1792. https://doi.org/10.1056/NEJMoa050518.

Berry, D., Cronin, K., Zelen, M., (2005). Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. The New England Journal of Medicine, 353, 1784-1792. https://doi.org/10.1056/NEJMoa050518. DOI: https://doi.org/10.1056/NEJMoa050518

Boulikas, T., Vougiouka, M. (2004). Recent Clinical Trials Using Cisplatin, Carboplatin and Their Combination Chemotherapy Drugs (Review). Oncology Reports, 11, 559-95. https://doi.org/10.3892/or.11.3.559. DOI: https://doi.org/10.3892/or.11.3.559

Brahmachari, B., Hazra, A. and Mazumdar, A. (2011). Adverse Drug Reaction Profile of Nanoparticle Versus Comventional Formulation of Paclitaxel : An Observational Study. Indian Journal of Pharmacology, 126-130. https://doi.org/10.4103/0253-7613.77341. DOI: https://doi.org/10.4103/0253-7613.77341

Cameron, D. A., Gabra, H. and Leonard, R. C. (1994). "Continuous 5-Flurouracil in the Treatment of Breast Cancer". British Journal of Cancer, 120-124. https://doi.org/10.1038/bjc.1994.259. DOI: https://doi.org/10.1038/bjc.1994.259

Castel, M., Despas,F. Modesto, A., Gales, C., Honton, B., Galinier, M., Senard, J. M., Pathak, A.(2013). Cardiotoxicity of Chemotherapies. Presse Med. 26-39. https://doi.org/10.1016/j.lpm.2012.04.014. DOI: https://doi.org/10.1016/j.lpm.2012.04.014

Chan, A., Su, C., De Boer, R.H., and Gajdatsy, A. (2013). Prevalence of Excessive Tearing In Women With Early Breast Cancer Receiving Adjuvant Docetaxel-Based Chemotherapy. Journal of Clinical Oncology, 31(17), 2123-2127. https://doi.org/10.1200/JCO.2012.45.6574. DOI: https://doi.org/10.1200/JCO.2012.45.6574

Coley, H.M. (2008). Mechanisms and Strategies to Overcome Chemotherapy Resistance in Metastatic Breast Cancer. Cancer Treatment Reviews , 34, 378-390. https://doi.org/10.1016/j.ctrv.2008.01.007. DOI: https://doi.org/10.1016/j.ctrv.2008.01.007

Crown, J., Hakes,T. and Reichman, B.(1993). Carboplatin and Etoposide In Metaststic Breast Cancer. Cancer 74, 1254-1257. DOI: https://doi.org/10.1002/1097-0142(19930215)71:4<1254::AID-CNCR2820710414>3.0.CO;2-X

Desantis, C., Siegel, R., Bandi, P., and Jemal, A. (2011). A Breast Cancer Statistics, 2011. CA : A Cancer Journal For Clinicians, 61, 408-418. https://doi.org/10.3322/caac.20134. DOI: https://doi.org/10.3322/caac.20134

Doroshow, J.H., Leong, L., Margolin, K. (1989). Refractory Metastatic Breast Cancer: Salvage Therapy with Fluorouraciland High-Dose Continuous Infusion Leucovorin Calcium. Journal of Clinical Oncology, 439-744. https://doi.org/10.1200/JCO.1989.7.4.439. DOI: https://doi.org/10.1200/JCO.1989.7.4.439

Ejlersten, B., Mouridsen, H.T., Jensen, M.B. (2008). Adjuvant Cyclophosphamide, Methotrexate and Fluorouracil in Premenopausal Patients with Node Positive Breast Cancer : Indirect Comparison of Dose and Schedule in DBCG Trials 77, 82 and 89. Acta Oncologica 47(4), 662-71. https://doi.org/10.1080/02841860801989761. DOI: https://doi.org/10.1080/02841860801989761

Emadi, A., Jones, R.J. and Brodsky, R.A. (2009). "Cyclophosphamide and Cancer : Golden Anniversary" Nature Review Clinical Oncology, 6, 638-647. https://doi.org/10.1038/nrclinonc.2009.146. DOI: https://doi.org/10.1038/nrclinonc.2009.146

Etienne, M-C., Guillot, T., Milano, G. (1996). Critical Factors Optimizing the 5-fluorouracil-Folinic Acid Association in Cancer Chemo-Therapy. Acta Oncologica, 7, 283-289. https://doi.org/10.1093/oxfordjournals.annonc.a010573. DOI: https://doi.org/10.1093/oxfordjournals.annonc.a010573

Ferlay, J., Colombet, M., Soerjomataram, I., Matthers, C., Parkin, D. M., Pineros, M., Znaor, A. and Bray, F. (2018). Estimating the Global Cancer Incidence and Mortality in 2018 : GLOBOCAN Sources and Methods International Journal of Cancer 1941-1953. https://doi.org/10.1002/ijc.31937. DOI: https://doi.org/10.1002/ijc.31937

Florea, A. M., and Busselberg, D. (2011). Cisplatin as an Antitumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers 3(1), 1351- 1371. https://doi.org/10.3390/cancers3011351. DOI: https://doi.org/10.3390/cancers3011351

Groopman, J.E., and Itri, L.M. (1999). Chemotherapy-Induced Anemia in Adults: Incidence and Treatment. Journal of the National Cancer Institute 91(19), 1616-34. https://doi.org/10.1093/jnci/91.19.1616. DOI: https://doi.org/10.1093/jnci/91.19.1616

Gabra, H., Cameron, D.A., Lee, L.E. and Mackay, J. (2020). Weekly Doxorubicin and Continuous Infusional Przemyslaw Kozminski, Pawel Krzysztof Halik, Raphael Chesori and Ewa Gniazdowska. Overview of Dual-Acting Drug Methotrexate in Different Neurological Disease, Autoimmune Pathologies and Cancer. International Journal of Molecular Sciences, 21(10). https://doi.org/10.3390/ijms21103483. DOI: https://doi.org/10.3390/ijms21103483

Ho, M. Y., and Mackey, J. R. (2014). Presentation and Management of Docetaxel-Related Adverse Effect in Patients With Breast Cancer. Cancer Management And Research 6, 253-259. https://doi.org/10.2147/CMAR.S40601. DOI: https://doi.org/10.2147/CMAR.S40601

Huang,L., Zeng, L. and Chu, Z. (2018). Chemoresistance-Related Long Non Coding RNA Expression Profiles in Human Breast Cancer Cells. Molecular Medicine Reports, 18(1), 243-253. https://doi.org/10.3892/mmr.2018.8942. DOI: https://doi.org/10.3892/mmr.2018.8942

Jasra, S. and Anampa, J. (2018). Anthracycline Use For Early Stage Breast Cancer in the Modern Era (2018) A Review. Current Treatment Options In Oncology. https://doi.org/10.1007/s11864-018-0547-8. DOI: https://doi.org/10.1007/s11864-018-0547-8

Khanna, C., Rosenberg, M. and Vail, D.M. (2015). A Review Of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs. Journal of Veterinary Internal Medicine 1006-1012. https://doi.org/10.1111/jvim.12596. DOI: https://doi.org/10.1111/jvim.12596

Kumar, P. Raza, K. Kaushik, L. and Malik, R. (2016). Role of Colloidal Drug Delivery Carriers In Taxane-Mediated Chemotherapy: A Review. Curr. Pharm. Des. 22, 5127-5143. https://doi.org/10.2174/1381612822666160524144926. DOI: https://doi.org/10.2174/1381612822666160524144926

Mansfield, C. M. (1993). "A Review of the Etiology of Breast Cancer". Journal of the National Medical Association, 217-221.

Mcgrogan, B.T., Gilmartin, B. and Carney, D.N. (2008). Taxanes, Microtubules and Chemoresistant Breast Cancer. Biochim. Biophys. Acta 1785, 96-132. https://doi.org/10.1016/j.bbcan.2007.10.004. DOI: https://doi.org/10.1016/j.bbcan.2007.10.004

Patt, D., Gauthier, M., Giordano, S. (2006). Paclitaxel in Breast Cancer. Women Health, 2(1), 11-21. https://doi.org/10.2217/17455057.2.1.11. DOI: https://doi.org/10.2217/17455057.2.1.11

Poi, M. J., Berger, M., and Lustberg, M. (2013). Docetaxel- Induce Skin Toxicities in Breast Cancer Patients Subsequent to Paclitaxel Shortage: A Case Series and Literature Review. Support Care Cancer 21(10), 2679-2686. https://doi.org/10.1007/s00520-013-1842-3. DOI: https://doi.org/10.1007/s00520-013-1842-3

Ribas, A., Albanell, J., Sole-Calvo, L. A. (1998). Cyclophosphamide, Methotrexate and Chronic Oral Tegafur Modulated by Folinic Acid in the Treatment of Patients with Advanced Breast Carcinoma. 22, 878-885. https://doi.org/10.1002/(SICI)1097-0142(19980301)82:5%3C878::AID-CNCR12%3E3.0.CO;2-Y. DOI: https://doi.org/10.1002/(SICI)1097-0142(19980301)82:5<878::AID-CNCR12>3.0.CO;2-Y

Seely, J. M. and Alhassan, T. (2018). Screening of Breast Cancer in 2018- What Should We Be Doing Today. Current Oncology, S115-S124. https://doi.org/10.3747/co.25.3770. DOI: https://doi.org/10.3747/co.25.3770

Shewach, D. S. and Kuchta, R. D. (2009). Introduction of Cancer Chemotherapeutics. Chem Rev 109(7), 2859-2861. https://doi.org/10.1021/cr900208x. DOI: https://doi.org/10.1021/cr900208x

Song, L., Zhang, Y. and He, J. (2011). The Side Effects of Docetaxel With Cyclophosphamide as Postoperative Adjuvant Chemotherapy for Elderly Breast Cancer Patients. Chinese- German Journal of Clinical Oncology, 391-393. https://doi.org/10.1007/s10330-011-0815-6. DOI: https://doi.org/10.1007/s10330-011-0815-6

Stark, L., Tofthage, C. and Mcmillan, S.C. (2012). The Symptoms Experience in Patients with Cancer. Journal of Hospice and Palliative Nursing 14(1), 61-70. https://doi.org/10.1097/NJH.0b013e318236de5c. DOI: https://doi.org/10.1097/NJH.0b013e318236de5c

Thorn, C. F., Oshiro, C. and Marsh, S. (2011). "Doxorubicin Pathways: Pharmacodynamics and Adverse Effects." Pharmacogenet Genomics (7) 440-446. https://doi.org/10.1097/FPC.0b013e32833ffb56. DOI: https://doi.org/10.1097/FPC.0b013e32833ffb56

Wang, L. Y., Xie, H., and Zhou, H. (2017). Efficacy of Carboplatin-Based Preoperative Chemotherapy for Triple-Negative Breast Cakkkmmincer. Saudi Medical Journal 38(1), 18-23. https://doi.org/10.15537/smj.2017.1.14969. DOI: https://doi.org/10.15537/smj.2017.1.14969

Yap,H. Y., Blumenchein, G. R., Tashima, C. K., And Wang, A. Y. (1979). High Dose Methotrexate For Advanced Breast Cancer. Cancer Treat Rep. 63(5), 757-761.

Zhang, D., Yangg, R., Wang, S. and Dong, Z. (2014). Paclitaxel New Uses for an Old Drug. Drug Design, Development and Therapy, 279-284. https://doi.org/10.2147/DDDT.S56801. DOI: https://doi.org/10.2147/DDDT.S56801




How to Cite

Saini, S. S., Zia, A., Tyagi, S., & Nautiyal, H. (2022). A RETROSPECTIVE AND PROSPECTIVE STUDY FOR ADVERSE DRUG REACTION OF CANCER CHEMOTHERAPY IN BREAST CANCER. International Journal of Research -GRANTHAALAYAH, 10(11), 255–273. https://doi.org/10.29121/granthaalayah.v10.i11.2022.4922